Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants

Edmund V. Capparelli, Barry T. Bloom, Tom J. Kueser, David G. Oelberg, Ellen M. Bifano, Robert D. White, Robert Schelonka, Stephen A. Pearlman, Joseph Patti, Seth V. Hetherington

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Nosocomial or late-onset sepsis is a common complication among premature infants, with a frequency inversely correlated with birth weight. Increased susceptibility to infection is due in part to an immature humoral (antibody-mediated) immune response. This study investigated the pharmacokinetics (PKs) and safety of a donor-selected specific intravenous immune globulin (IVIG) preparation, INH-A21 (Veronate), for prevention of sepsis in premature infants. Thirty-six infants weighing between 500 and 1,250 g during the first postnatal week were eligible to begin a series of up to four intravenous infusions of 500 or 750 mg/kg of body weight INH-A21. Blood samples were analyzed for antibodies against the Ser-Asp dipeptide repeat G (SdrG) and clumping factor A (ClfA) surface proteins of staphylococci. Sparse sampling and population PK analyses were performed to derive PK parameters. Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively. The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively. In the final model, the values of the PK parameters were independent of gestational age. Both doses of INH-A21 were well tolerated, and the safety profile was similar to those of other IVIG preparations. These results suggest that a shorter dosing interval should be utilized between the first and second doses to achieve and maintain higher titers of anti-ClfA and anti-SdrG antibodies. Further studies examining INH-A21 for the prevention of late-onset sepsis in infants within the weight range studied are warranted.

Original languageEnglish (US)
Pages (from-to)4121-4127
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume49
Issue number10
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Low Birth Weight Infant
Dipeptides
Multicenter Studies
Immunoglobulins
Tissue Donors
Safety
Pharmacokinetics
Antibodies
Sepsis
Intravenous Immunoglobulins
Premature Infants
Staphylococcus
Intravenous Infusions
Birth Weight
Gestational Age
Membrane Proteins
Body Weight
Veronate
Weights and Measures
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants. / Capparelli, Edmund V.; Bloom, Barry T.; Kueser, Tom J.; Oelberg, David G.; Bifano, Ellen M.; White, Robert D.; Schelonka, Robert; Pearlman, Stephen A.; Patti, Joseph; Hetherington, Seth V.

In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 10, 10.2005, p. 4121-4127.

Research output: Contribution to journalArticle

Capparelli, Edmund V. ; Bloom, Barry T. ; Kueser, Tom J. ; Oelberg, David G. ; Bifano, Ellen M. ; White, Robert D. ; Schelonka, Robert ; Pearlman, Stephen A. ; Patti, Joseph ; Hetherington, Seth V. / Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants. In: Antimicrobial Agents and Chemotherapy. 2005 ; Vol. 49, No. 10. pp. 4121-4127.
@article{1b0aee04d1c74523bfa30742b3baf55f,
title = "Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants",
abstract = "Nosocomial or late-onset sepsis is a common complication among premature infants, with a frequency inversely correlated with birth weight. Increased susceptibility to infection is due in part to an immature humoral (antibody-mediated) immune response. This study investigated the pharmacokinetics (PKs) and safety of a donor-selected specific intravenous immune globulin (IVIG) preparation, INH-A21 (Veronate), for prevention of sepsis in premature infants. Thirty-six infants weighing between 500 and 1,250 g during the first postnatal week were eligible to begin a series of up to four intravenous infusions of 500 or 750 mg/kg of body weight INH-A21. Blood samples were analyzed for antibodies against the Ser-Asp dipeptide repeat G (SdrG) and clumping factor A (ClfA) surface proteins of staphylococci. Sparse sampling and population PK analyses were performed to derive PK parameters. Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively. The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively. In the final model, the values of the PK parameters were independent of gestational age. Both doses of INH-A21 were well tolerated, and the safety profile was similar to those of other IVIG preparations. These results suggest that a shorter dosing interval should be utilized between the first and second doses to achieve and maintain higher titers of anti-ClfA and anti-SdrG antibodies. Further studies examining INH-A21 for the prevention of late-onset sepsis in infants within the weight range studied are warranted.",
author = "Capparelli, {Edmund V.} and Bloom, {Barry T.} and Kueser, {Tom J.} and Oelberg, {David G.} and Bifano, {Ellen M.} and White, {Robert D.} and Robert Schelonka and Pearlman, {Stephen A.} and Joseph Patti and Hetherington, {Seth V.}",
year = "2005",
month = "10",
doi = "10.1128/AAC.49.10.4121-4127.2005",
language = "English (US)",
volume = "49",
pages = "4121--4127",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human staphylococcal immune globulin, in low-birth-weight infants

AU - Capparelli, Edmund V.

AU - Bloom, Barry T.

AU - Kueser, Tom J.

AU - Oelberg, David G.

AU - Bifano, Ellen M.

AU - White, Robert D.

AU - Schelonka, Robert

AU - Pearlman, Stephen A.

AU - Patti, Joseph

AU - Hetherington, Seth V.

PY - 2005/10

Y1 - 2005/10

N2 - Nosocomial or late-onset sepsis is a common complication among premature infants, with a frequency inversely correlated with birth weight. Increased susceptibility to infection is due in part to an immature humoral (antibody-mediated) immune response. This study investigated the pharmacokinetics (PKs) and safety of a donor-selected specific intravenous immune globulin (IVIG) preparation, INH-A21 (Veronate), for prevention of sepsis in premature infants. Thirty-six infants weighing between 500 and 1,250 g during the first postnatal week were eligible to begin a series of up to four intravenous infusions of 500 or 750 mg/kg of body weight INH-A21. Blood samples were analyzed for antibodies against the Ser-Asp dipeptide repeat G (SdrG) and clumping factor A (ClfA) surface proteins of staphylococci. Sparse sampling and population PK analyses were performed to derive PK parameters. Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively. The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively. In the final model, the values of the PK parameters were independent of gestational age. Both doses of INH-A21 were well tolerated, and the safety profile was similar to those of other IVIG preparations. These results suggest that a shorter dosing interval should be utilized between the first and second doses to achieve and maintain higher titers of anti-ClfA and anti-SdrG antibodies. Further studies examining INH-A21 for the prevention of late-onset sepsis in infants within the weight range studied are warranted.

AB - Nosocomial or late-onset sepsis is a common complication among premature infants, with a frequency inversely correlated with birth weight. Increased susceptibility to infection is due in part to an immature humoral (antibody-mediated) immune response. This study investigated the pharmacokinetics (PKs) and safety of a donor-selected specific intravenous immune globulin (IVIG) preparation, INH-A21 (Veronate), for prevention of sepsis in premature infants. Thirty-six infants weighing between 500 and 1,250 g during the first postnatal week were eligible to begin a series of up to four intravenous infusions of 500 or 750 mg/kg of body weight INH-A21. Blood samples were analyzed for antibodies against the Ser-Asp dipeptide repeat G (SdrG) and clumping factor A (ClfA) surface proteins of staphylococci. Sparse sampling and population PK analyses were performed to derive PK parameters. Following administration of the 500- and 750-mg/kg doses, the estimated average steady-state levels of anti-ClfA were 6.1 U/ml and 9.2 U/ml, respectively, and those of anti-SdrG were 5.2 U/ml and 7.7 U/ml, respectively. The elimination half-lives for anti-ClfA and anti-SdrG were 719 h and 701 h, respectively, and the clearances were 0.18 ml/h and 0.21 ml/h, respectively. In the final model, the values of the PK parameters were independent of gestational age. Both doses of INH-A21 were well tolerated, and the safety profile was similar to those of other IVIG preparations. These results suggest that a shorter dosing interval should be utilized between the first and second doses to achieve and maintain higher titers of anti-ClfA and anti-SdrG antibodies. Further studies examining INH-A21 for the prevention of late-onset sepsis in infants within the weight range studied are warranted.

UR - http://www.scopus.com/inward/record.url?scp=25844451014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844451014&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.10.4121-4127.2005

DO - 10.1128/AAC.49.10.4121-4127.2005

M3 - Article

VL - 49

SP - 4121

EP - 4127

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -